Literature DB >> 3499997

Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography.

P T O'Gara1, R O Bonow, B J Maron, B A Damske, A Van Lingen, S L Bacharach, S M Larson, S E Epstein.   

Abstract

Myocardial ischemia may play a critical role in the symptomatic presentation and natural history of hypertrophic cardiomyopathy (HCM). To assess the relative prevalence and functional significance of myocardial perfusion abnormalities in patients comprising the broad clinical spectrum of HCM, we studied 72 patients (ages 12 to 69 years, mean 40) using thallium-201 emission computed tomography. Imaging was performed immediately after maximal exercise and again after a 3 hr delay. Regional perfusion defects were identified in 41 of the 72 patients (57%). Fixed or only partially reversible defects were evident in 17 patients, 14 of whom (82%) had left ventricular ejection fractions of less than 50% at rest. Twenty-four patients demonstrated perfusion defects during exercise that completely reversed at rest; all had normal or hyperdynamic left ventricular systolic function (ejection fraction greater than or equal to 50%). Perfusion abnormalities were present in all regions of the left ventricle. However, the fixed defects were observed predominantly in segments of the left ventricular wall that were of normal or only mildly increased (15 to 20 mm) thickness; in contrast, a substantial proportion (41%) of the completely reversible defects occurred in areas of moderate-to-marked wall thickness (greater than or equal to 20 mm, p less than .001). Neither a history of chest pain nor its provocation with treadmill exercise was predictive of an abnormal thallium study, since regional perfusion defects were present in 10 of 18 (56%) completely asymptomatic patients, compared with 31 of 54 (58%) symptomatic patients. These data indicate that myocardial perfusion abnormalities occur commonly among patients with HCM. Fixed or only partially reversible defects suggestive of myocardial scar and/or severe ischemia occur primarily in patients with impaired systolic performance. Completely reversible perfusion abnormalities occur predominantly in patients with normal or supranormal left ventricular systolic function. Such dynamic changes in regional thallium activity may reflect an ischemic process that contributes importantly to the clinical manifestations and natural history of HCM.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499997     DOI: 10.1161/01.cir.76.6.1214

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  41 in total

1.  Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation.

Authors:  Felix Y j Keng; Su Min Chang; Eduardo Cwajg; Zuo-Xiang He; Nasser M Lakkis; Sherif F Nagueh; William H Spencer; Mario S Verani
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

2.  Left ventricular dysfunction and HLA Bw52 antigen in Takayasu arteritis.

Authors:  K Kasuya; Y Hashimoto; F Numano
Journal:  Heart Vessels Suppl       Date:  1992

Review 3.  Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging.

Authors:  C Y Loong; C Anagnostopoulos
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 4.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

5.  Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy.

Authors:  Shinro Matsuo; Yasuyuki Nakamura; Takayoshi Tsutamoto; Masahiko Kinoshita
Journal:  J Nucl Cardiol       Date:  2002 Jul-Aug       Impact factor: 5.952

Review 6.  Metabolic imaging using SPECT.

Authors:  Junichi Taki; Ichiro Matsunari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

7.  Reversible ischaemia in hypertrophic cardiomyopathy.

Authors:  H Thomson; W Fong; W Stafford; M Frenneaux
Journal:  Br Heart J       Date:  1995-09

8.  Prognosis of hypertrophic cardiomyopathy: assessment by 123I-BMIPP (beta-methyl-p-(123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography.

Authors:  T Nishimura; S Nagata; T Uehara; T Morozumi; Y Ishida; T Nakata; O Iimura; C Kurata; Y Wakabayashi; H Sugihara; K Otsuki; T Wada; Y Koga
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

9.  Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy.

Authors:  M Shimizu; N Sugihara; Y Kita; K Shimizu; Y Horita; K Nakajima; J Taki; R Takeda
Journal:  Br Heart J       Date:  1992-02

10.  Vagal enhancement linking abnormal blood pressure response and subendocardial ischemia in hypertrophic cardiomyopathy.

Authors:  Tatsuya Kawasaki; Hiroki Sugihara
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09-09       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.